Levels = Thursday 30 April US close / latest Asia overnight read. Bloomberg Europe tab failed to load this run; figures cross-checked against Reuters, CNBC and FXStreet.
| Instrument | Last | Change |
|---|---|---|
| S&P 500 (cash, prior close) | 7,209.01 | +1.02% |
| Nasdaq Composite (cash) | 24,892.31 | +0.89% |
| Dow Jones (cash) | 49,652.14 | +1.62% |
| FTSE 100 (prior close) | ~10,210 | London open today |
| US 10y Treasury | 4.42% | +7 bps WTD |
| EUR/USD | ~1.17 | range-bound |
| GBP/USD | ~1.34 | flat |
| Brent crude | ~$118 | peaked $126 intraday |
| WTI crude | ~$107 | multi-year highs |
| Gold | near record | safe-haven bid |
Crude is still the single most important price in the room. Brent printed a fresh 2026 high above $126 intraday on Thursday before settling near $118 as the U.S. floated an international "maritime freedom" coalition to try to restart Hormuz traffic. The IRGC's published "alternative routes" still channel tankers through Iranian territorial waters past Larak Island — a non-starter for most insurers and most Western flag-states, which is why throughput sits near 5% of normal.
Two adjacent geopolitical threads to watch into the long weekend. First, the Putin–Trump call has put a May 9 Victory Day truce on the table; Kyiv is treating it as a trial balloon and pushing instead for a durable ceasefire with security guarantees. Second, Trump's planned Beijing visit and the in-flight U.S.–China "Board of Trade" mechanism — essentially managed bilateral trade — keep tariff risk on a lower simmer than at peak, with the effective average tariff at ~11.8% after court rulings and rollbacks. None of this changes today's tape much, but each is a 2026 fault line.
The Apple print last night is the clean read for the day. Top-line beat ($111.2bn vs $109.7bn), services and gross margin both above the Street, and a +3% AH move into a US session most of Europe will miss. The thing to file away is the memory-cost commentary: Cook explicitly flagged DRAM/NAND inflation as a multi-quarter margin headwind. That ties directly to the AI-buildout-driven HBM shortage and is consistent with Meta's $19.84bn quarterly capex, Alphabet's record Cloud revenue, and the broader hyperscaler spend picture.
The split-tape conclusion from this week's earnings: capex monetisation is fine where customers exist (Alphabet, Qualcomm), uncomfortable where the path is more speculative (Meta). For a doctor watching this from a sector-rotation lens, the read-through into healthcare is via Eli Lilly (+9% on weight-loss drug strength) — incretins are still the single biggest pharma earnings story of 2026, and the HBM/memory shortage matters for medical-imaging silicon as much as for hyperscaler GPUs.
With most exchanges shut today there is no European cash open to react to. The setup into Monday: Stoxx 600 closed up roughly 1.4% on Wednesday (last reading before today's holiday-thin tape), buoyed by ECB and BoE having already moved through their rate windows and by the Iran-war oil tail being partially priced in. The big swing factor for next week is whether Brent stays above $115 — at that level European industrial earnings start to crack visibly, particularly in chemicals and autos.
The UK is open. FTSE 100 remains the relative European winner in an oil-up, miners-up regime, and London should trade cleanly today even if continental volume is light. Watch sterling: GBP/USD has shown more trend than EUR/USD in recent weeks, and any UK-specific data surprise next week into BoE meetings will move it.
Mainland China and Hong Kong are closed for the Labour Day holiday — no fresh A-share or H-share read until next week. Japan is technically open but heading into Golden Week (3–5 May closures); volumes will be thinner than usual and the BOJ's stance on the yen, still hovering near multi-year lows against the dollar, remains the macro pressure point. Korea (Kospi) and India (Sensex/Nifty closed for Maharashtra Day) provide the only real Asia-EM signal.
The structural Asia story this week was Bloomberg's Big Take flagging that North Korea's nuclear arsenal is outpacing U.S. missile defence calculations — a slow-burn shift in Pacific deterrence that is starting to show up in Japan and Korea defence-spending debates and, downstream, in defence-equity bid lists.
Two threads relevant to a clinician. First, Eli Lilly's blow-out quarter was again carried by tirzepatide and the broader incretin franchise — payer pushback on coverage breadth is the next leg of that story, and it interacts with U.S. Medicare price-negotiation timelines. Second, U.S. cross-border medical-device regulation continues to look unusual: a U.S. brain-implant company has reportedly run a first human test in China, an arbitrage of FDA timelines that will draw scrutiny. Worth keeping an eye on if you follow the AI-in-medicine pipeline — neural interfaces are the most regulator-sensitive corner of it.